Smartest Doc
Inadequate reporting of concomitant drug treatment in cardiovascular interventional head-to-head trials Full Text
Clinical Cardiology, 04/26/2012
Mahfoud F et al. – Poor reporting of medical treatment at discharge might reflect an underestimation of secondary prevention in patients undergoing cardiac surgery or interventional procedures in head–to–head interventional trials. Thus, discussion of optimal revascularization procedure has to remain open, even in terms of concomitant medical treatment of patients.
Methods- A systematic search of the literature regarding documentation and reports of medical treatment in cardiovascular interventional head–to–head trials with more than 500 patients comparing CABG and PCI was performed.
- Systematic research of the literature identified 2106 articles of potential interest.
- After review and selection, only 3 trials reported on medical treatment.
- Baseline medication was reported in the RITA (Randomized Intervention Treatment of Angina), CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation), and SYNTAX trials, and follow–up data were provided by the CABRI and SYNTAX 3–year trials only.